NDAORALTABLET
Approved
Jun 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
MONOKET (isosorbide mononitrate) by Alkermes is clinical pharmacology: isosorbide mononitrate is the major active metabolite of isosorbide dinitrate (isdn), and most of the clinical activity of the dinitrate is attributable to the mononitrate. First approved in 1993.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONOKET (isosorbide mononitrate) is an oral nitrate vasodilator approved in 1993 for the treatment of angina pectoris. It works by relaxing vascular smooth muscle, dilating peripheral arteries and veins, and reducing cardiac preload and afterload. The drug is the active metabolite of isosorbide dinitrate and has nearly 100% bioavailability with rapid GI absorption.
LOE Approaching
Product is in LOE-approaching phase with modest competitive pressure (30/100), suggesting a stabilizing brand team managing generic transition rather than growth expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY: Isosorbide mononitrate is the major active metabolite of isosorbide dinitrate (ISDN), and most of the clinical activity of the dinitrate is attributable to the mononitrate. The principal pharmacological action of isosorbide mononitrate is relaxation of vascular smooth muscle…
Worked on MONOKET at Alkermes? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.